Table of Contents Author Guidelines Submit a Manuscript
Journal of Tropical Medicine
Volume 2017 (2017), Article ID 5629130, 6 pages
https://doi.org/10.1155/2017/5629130
Research Article

Liver Fibrosis and Hepatitis B Coinfection among ART Naïve HIV-Infected Patients at a Tertiary Level Hospital in Northwestern Tanzania: A Cross-Sectional Study

1Department of Medicine, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania
2Department of Medicine, Bugando Medical Centre, P.O. Box 1370, Mwanza, Tanzania
3Department of Medicine, College of Health Sciences, The University of Dodoma, P.O. Box 395, Dodoma, Tanzania

Correspondence should be addressed to Semvua B. Kilonzo

Received 2 May 2017; Revised 11 June 2017; Accepted 22 June 2017; Published 30 July 2017

Academic Editor: Marcel Tanner

Copyright © 2017 Semvua B. Kilonzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Alter, “Epidemiology of viral hepatitis and HIV co-infection,” Journal of Hepatology, vol. 44, pp. S6–S9, 2006. View at Publisher · View at Google Scholar
  2. L. Stabinski, S. O'Connor, M. Barnhart, R. J. Kahn, and T. E. Hamm, “Prevalence of HIV and Hepatitis B virus co-infection in Sub-Saharan Africa and the potential impact and program feasibility of Hepatitis B surface antigen screening in resource-limited settings,” Journal of Acquired Immune Deficiency Syndromes, vol. 68, pp. S274–S285, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Hawkins, B. Christian, J. Ye et al., “Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania,” AIDS, vol. 27, no. 6, pp. 919–927, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Velen, S. Charalambous, C. Innes, G. J. Churchyard, and C. J. Hoffmann, “Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study,” HIV Medicine, vol. 17, no. 9, pp. 702–707, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Wandeler, T. Gsponer, F. Bihl et al., “Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study,” Journal of Infectious Diseases, vol. 208, no. 9, pp. 1454–1458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Pol, P. Lebray, and A. Vallet-Pichard, “HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms,” Clinical Infectious Diseases, vol. 38, supplement 2, pp. S65–S72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. World Health Organization, Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, Geneva, Switzerland, 2015.
  8. L. Stabinski, S. J. Reynolds, P. Ocama et al., “High prevalence of liver fibrosis associated with HIV infection: A study in rural Rakai, Uganda,” Antiviral Therapy, vol. 16, no. 3, pp. 405–411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Ramírez-Mena, T. R. Glass, A. Winter et al., “Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort,” Open Forum Infectious Diseases, vol. 3, no. 3, p. ofw162, 2016. View at Publisher · View at Google Scholar
  10. Hepatitis C Online, http://www.hepatitisc.uw.edu/page/clinical-calculators/apri.
  11. B. M. Muriuki, M. M. Gicheru, D. Wachira, A. K. Nyamache, and S. A. Khamadi, “Prevalence of hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya,” BMC Research Notes, vol. 6, no. 1, article no. 363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Ocama, E. Seremba, B. Apica, and K. Opio, “Hepatitis b and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda,” African Health Sciences, vol. 15, no. 2, pp. 328–333, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Hamers, H. L. Zaaijer, C. L. Wallis et al., “HIV-HBV coinfection in Southern Africa and the effect of Lamivudine- Versus tenofovir-containing cART on HBV outcomes,” Journal of Acquired Immune Deficiency Syndromes, vol. 64, no. 2, pp. 174–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C. L. Thio, L. Smeaton, M. Saulynas et al., “Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort,” AIDS, vol. 27, no. 2, pp. 191–201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. C. Franzeck, R. Ngwale, B. Msongole et al., “Viral Hepatitis and Rapid Diagnostic Test Based Screening for HBsAg in HIV-infected Patients in Rural Tanzania,” PLoS ONE, vol. 8, no. 3, Article ID e58468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. TACAIDS, “National Guidelines for the Management of HIV and AIDS,” Dar es Salaam, Tanzania, 2012, http://www.nacp.go.tz/site/download/nationalguideline42012.pdf.
  17. M. J. Mphahlele, A. Lukhwareni, R. J. Burnett, L. M. Moropeng, and J. M. Ngobeni, “High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa,” Journal of Clinical Virology, vol. 35, no. 1, pp. 14–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. T. Cohen Stuart, M. Velema, R. Schuurman, C. A. B. Boucher, and A. I. M. Hoepelman, “Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy,” Journal of Medical Virology, vol. 81, no. 3, pp. 441–445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Matthews, J. Neuhaus, S. Bhagani et al., “Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial,” HIV Medicine, vol. 16, no. 1, pp. 129–136, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. B. G. Kapogiannis, E. Leister, G. K. Siberry et al., “Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth,” AIDS, vol. 30, no. 6, pp. 889–898, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Gitau, S. Vinayak, M. Silaba, R. Adam, and R. Shah, “High Prevalence of Liver Fibrosis in Patients with Human Immunodeficiency Virus Monoinfection and Human Immunodeficiency Virus Hepatitis-B Co-infection as Assessed by Shear Wave Elastography: Study at a Teaching Hospital in Kenya,” Journal of Clinical Imaging Science, vol. 6, no. 1, p. 22, 2016. View at Publisher · View at Google Scholar
  22. M. O. Iroezindu, O. O. Agbaji, C. A. Daniyam, G. C. Isiguzo, C. Isichei, and M. O. Akanbi, “Liver function test abnormalities in Nigerian patients with human immunodeficiency virus and hepatitis B virus co-infection,” International Journal of STD and AIDS, vol. 24, no. 6, pp. 461–467, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. D. C. Rockey, S. H. Caldwell, Z. D. Goodman, R. C. Nelson, and A. D. Smith, “Liver biopsy,” Hepatology, vol. 49, no. 3, pp. 1017–1044, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Regev, M. Berho, L. J. Jeffers et al., “Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection,” The American Journal of Gastroenterology, vol. 97, no. 10, pp. 2614–2618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. T. B. Kelleher, S. H. Mehta, R. Bhaskar et al., “Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index,” Journal of Hepatology, vol. 43, no. 1, pp. 78–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. W. G. Shin, S. H. Park, M. K. Jang et al., “Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B,” Digestive and Liver Disease, vol. 40, no. 4, pp. 267–274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. B. K. Kim, D. Y. Kim, J. Y. Park et al., “Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients,” Liver International, vol. 30, no. 4, pp. 546–553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Stockdale, R. O. Phillips, A. M. Geretti et al., “The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: 'The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa' by Lemoine et al,” Gut, vol. 65, no. 5, pp. 882–884, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Trang, J. R. Petersen, and N. Snyder, “Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: Comparison of the APRI and FIB-4 index,” Clinica Chimica Acta, vol. 397, no. 1-2, pp. 51–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. K. Sarin, M. Kumar, G. K. Lau et al., “Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update,” Hepatology International, vol. 10, no. 1, pp. 1–98, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. European Association for the Study of the Liver, “EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis,” Journal of Hepatology, vol. 63, no. 1, pp. 237–264, 2015. View at Publisher · View at Google Scholar